Articles
03.10.2019
Pricing and market access launch excellence

This study aims to understand the industry perspective on drivers and challenges for a successful la...

Read more
Articles
26.09.2019
New reference pricing rules for Greece 2019

Medicine prices in Greece are set by the IRP. IRP is the process of using the prices in other countr...

Read more
Articles
13.09.2019
Evidence base for Yescarta and Kymriah

Is the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...

Read more
Articles
04.09.2019
Gene therapies and Managed Entry Agreements

Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...

Read more
Articles
04.09.2019
Are access agreements essential for NICE access

This study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...

Read more
Articles
13.08.2019
Is market access for oncology treatments easier in

This study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...

Read more
Articles
31.07.2019
Commercial patient access scheme

In England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...

Read more
Articles
27.06.2019
Joint pricing assessment in Europe

By joining together, countries can combine their resources to potentially increase the efficiency of...

Read more
Articles
29.05.2019
What are precision medicines

What is the future of precision medicine in the EU? The field of precision medicine is a complex are...

Read more
Articles
28.05.2019
NICE scientific advice re Brexit

NICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.